Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
1
20%
Ph phase_3
1
20%
Ph not_applicable
1
20%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(1)
Other(2)

Detailed Status

Completed2
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
N/A1 (20.0%)

Trials by Status

terminated120%
completed240%
unknown240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

NCT03563560
unknownnot_applicable

AML Treatment in Untreated Adult Patients

NCT00449319
completedphase_3

DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML

NCT00589082
terminatedphase_1

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

NCT00219765
unknownphase_2

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

NCT00209833

Clinical Trials (5)

Showing 5 of 5 trials
NCT03563560Phase 1

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Completed
NCT00449319Not Applicable

AML Treatment in Untreated Adult Patients

Unknown
NCT00589082Phase 3

DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML

Completed
NCT00219765Phase 1

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

Terminated
NCT00209833Phase 2

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5